Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Physiological Research · 31.08.2024 · (Suppl 1) · S377-S387
DOI: 10.33549/physiolres.935364 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiological Research, erschienen am 31.08.2024. Verfasst von I Vaněčková und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Hypertension, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. ivana.vaneckova@fgu.cas.cz. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
A new class of antidiabetic drugs - gliflozins (inhibitors of sodium glucose cotransporter-2; SGLT-2i) stimulate glucose and sodium excretion, thereby contributing to improved glycemic control, weight loss and blood pressure reduction in diabetic patients. Large clinical trials in patients with type 2 diabetes treated with empagliflozin, canagliflozin or dapagliflozin have demonstrated their excellent efficacy in improving many cardiovascular outcomes, including the reduction of death from cardiovascular diseases, non-fatal myocardial infarction or stroke, and hospitalization for heart failure. Moreover, the beneficial effects of SGLT-2i were also demonstrated in the decrease in proteinuria, which leads to a lower risk of progression to end-stage renal disease and thus a delay in initiation of the renal replacement therapy. Unexpectedly, their cardioprotective and renoprotective effects have been demonstrated not only in patients with diabetes but also in those without diabetes. Recently, much effort has been focused on patients with heart failure (either with reduced or preserved ejection fraction) or liver disease. Experimental studies have highlighted pleiotropic effects of SGLT-2 inhibitors beyond their natriuretic and glycosuric effects, including reduction of fibrosis, inflammation, reactive oxygen species, and others. Our results in experimental non-diabetic models of hypertension, chronic kidney disease and heart failure are partially consistent with these findings. This raises the question of whether the same mechanisms are at work in diabetic and non-diabetic conditions, and which mechanisms are responsible for the beneficial effects of gliflozins under non-diabetic conditions. Are these effects cardio-renal, metabolic, or others? This review will focus on the effects of gliflozins under different pathophysiological conditions, namely in hypertension, chronic kidney disease, and heart failure, which have been evaluated in non-diabetic rat models of these diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Hypertension, Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic. ivana.vaneckova@fgu.cas.cz.
Zitieren
APA
Vaněčková, I., & Zicha, J. (2024). Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases. Physiological Research, S377-S387. https://doi.org/10.33549/physiolres.935364
Vancouver
Vaněčková I, Zicha J. Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases. Physiological Research. 2024:S377-S387. doi:10.33549/physiolres.935364
BibTeX
@article{Vankov2024,
author = {Vaněčková, I and Zicha, J},
title = {Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases},
journal = {Physiological Research},
year = {2024},
number = {Suppl 1},
pages = {S377--S387},
doi = {10.33549/physiolres.935364}
}
EUVIMED